Utilization of the human cell line HL-60 for chemiluminescence based detection of microorganisms and related substances

Research output: Contribution to journalJournal articlepeer-review

Standard

Utilization of the human cell line HL-60 for chemiluminescence based detection of microorganisms and related substances. / Timm, Michael; Hansen, Erik W; Moesby, Lise; Christensen, Jens D.

In: European Journal of Pharmaceutical Sciences, Vol. 27, No. 2-3, 2006, p. 252-8.

Research output: Contribution to journalJournal articlepeer-review

Harvard

Timm, M, Hansen, EW, Moesby, L & Christensen, JD 2006, 'Utilization of the human cell line HL-60 for chemiluminescence based detection of microorganisms and related substances', European Journal of Pharmaceutical Sciences, vol. 27, no. 2-3, pp. 252-8. https://doi.org/10.1016/j.ejps.2005.10.006

APA

Timm, M., Hansen, E. W., Moesby, L., & Christensen, J. D. (2006). Utilization of the human cell line HL-60 for chemiluminescence based detection of microorganisms and related substances. European Journal of Pharmaceutical Sciences, 27(2-3), 252-8. https://doi.org/10.1016/j.ejps.2005.10.006

Vancouver

Timm M, Hansen EW, Moesby L, Christensen JD. Utilization of the human cell line HL-60 for chemiluminescence based detection of microorganisms and related substances. European Journal of Pharmaceutical Sciences. 2006;27(2-3):252-8. https://doi.org/10.1016/j.ejps.2005.10.006

Author

Timm, Michael ; Hansen, Erik W ; Moesby, Lise ; Christensen, Jens D. / Utilization of the human cell line HL-60 for chemiluminescence based detection of microorganisms and related substances. In: European Journal of Pharmaceutical Sciences. 2006 ; Vol. 27, No. 2-3. pp. 252-8.

Bibtex

@article{d67a39ccb4b44ecfb04cf29af046134c,
title = "Utilization of the human cell line HL-60 for chemiluminescence based detection of microorganisms and related substances",
abstract = "In this paper we describe a new pyrogen assay using the human leukemia cell line HL-60. The cell line is differentiated using all-trans retinoic acid (ATRA) to generate a cell population that resembles mature granulocytes. The differentiated HL-60 cell is capable of generating reactive oxygen species (ROS) when challenged with pyrogenic substances. In a luminol enhanced chemilumimetric assay the responsiveness of differentiated HL-60 cells is tested towards Salmonella typhimurium, Bacillus subtilis, Saccharomyces cerevisiae, Candida albicans, lipopolysaccharide (LPS) and lipoteichoic acid (LTA). The results show a poor sensitivity to S. typhimurium but displays good sensitivity towards B. subtilis, LTA and LPS. Furthermore, the sensitivity towards the yeasts C. albicans and S. cerevisiae is considerably better than obtained in other in vitro cell systems. Overall these results indicate that the HL-60 cell assay possibly could be evolved to a supplementary assay for the known pyrogenic detection assays. Furthermore, the utilization of the assay for pyrogenic examination of recombinant drugs derived from yeast expression systems would be relevant to examine.",
keywords = "Former Faculty of Pharmaceutical Sciences",
author = "Michael Timm and Hansen, {Erik W} and Lise Moesby and Christensen, {Jens D}",
year = "2006",
doi = "10.1016/j.ejps.2005.10.006",
language = "English",
volume = "27",
pages = "252--8",
journal = "Norvegica Pharmaceutica Acta",
issn = "0928-0987",
publisher = "Elsevier",
number = "2-3",

}

RIS

TY - JOUR

T1 - Utilization of the human cell line HL-60 for chemiluminescence based detection of microorganisms and related substances

AU - Timm, Michael

AU - Hansen, Erik W

AU - Moesby, Lise

AU - Christensen, Jens D

PY - 2006

Y1 - 2006

N2 - In this paper we describe a new pyrogen assay using the human leukemia cell line HL-60. The cell line is differentiated using all-trans retinoic acid (ATRA) to generate a cell population that resembles mature granulocytes. The differentiated HL-60 cell is capable of generating reactive oxygen species (ROS) when challenged with pyrogenic substances. In a luminol enhanced chemilumimetric assay the responsiveness of differentiated HL-60 cells is tested towards Salmonella typhimurium, Bacillus subtilis, Saccharomyces cerevisiae, Candida albicans, lipopolysaccharide (LPS) and lipoteichoic acid (LTA). The results show a poor sensitivity to S. typhimurium but displays good sensitivity towards B. subtilis, LTA and LPS. Furthermore, the sensitivity towards the yeasts C. albicans and S. cerevisiae is considerably better than obtained in other in vitro cell systems. Overall these results indicate that the HL-60 cell assay possibly could be evolved to a supplementary assay for the known pyrogenic detection assays. Furthermore, the utilization of the assay for pyrogenic examination of recombinant drugs derived from yeast expression systems would be relevant to examine.

AB - In this paper we describe a new pyrogen assay using the human leukemia cell line HL-60. The cell line is differentiated using all-trans retinoic acid (ATRA) to generate a cell population that resembles mature granulocytes. The differentiated HL-60 cell is capable of generating reactive oxygen species (ROS) when challenged with pyrogenic substances. In a luminol enhanced chemilumimetric assay the responsiveness of differentiated HL-60 cells is tested towards Salmonella typhimurium, Bacillus subtilis, Saccharomyces cerevisiae, Candida albicans, lipopolysaccharide (LPS) and lipoteichoic acid (LTA). The results show a poor sensitivity to S. typhimurium but displays good sensitivity towards B. subtilis, LTA and LPS. Furthermore, the sensitivity towards the yeasts C. albicans and S. cerevisiae is considerably better than obtained in other in vitro cell systems. Overall these results indicate that the HL-60 cell assay possibly could be evolved to a supplementary assay for the known pyrogenic detection assays. Furthermore, the utilization of the assay for pyrogenic examination of recombinant drugs derived from yeast expression systems would be relevant to examine.

KW - Former Faculty of Pharmaceutical Sciences

U2 - 10.1016/j.ejps.2005.10.006

DO - 10.1016/j.ejps.2005.10.006

M3 - Journal article

C2 - 16310347

VL - 27

SP - 252

EP - 258

JO - Norvegica Pharmaceutica Acta

JF - Norvegica Pharmaceutica Acta

SN - 0928-0987

IS - 2-3

ER -

ID: 37759437